bluebird bio Inc and Novo Nordisk A/S have entered into a research collaboration to jointly develop in vivo genome editing treatments for genetic diseases, including haemophilia. During a three year research collaboration, the two companies will focus on identifying a gene therapy candidate for haemophilia A.
